Cargando…
Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes
INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981669/ https://www.ncbi.nlm.nih.gov/pubmed/36876083 http://dx.doi.org/10.3389/fmicb.2023.1118000 |
_version_ | 1784900157997842432 |
---|---|
author | Yen, Fu-Shun Wei, James Cheng-Chung Hung, Yu-Tung Hsu, Chung Y. Hwu, Chii-Min Hsu, Chih-Cheng |
author_facet | Yen, Fu-Shun Wei, James Cheng-Chung Hung, Yu-Tung Hsu, Chung Y. Hwu, Chii-Min Hsu, Chih-Cheng |
author_sort | Yen, Fu-Shun |
collection | PubMed |
description | INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between January 1, 2000, and December 31, 2017. The Cox proportional hazards models were used for comparing the risk of morbidity and mortality associated with pneumonias. RESULTS: Compared with the nonuse of TZDs, the adjusted hazard ratios (95% CI) for TZD use in hospitalization for all-cause pneumonia, bacterial pneumonia, invasive mechanical ventilation, and death due to pneumonia were 0.92 (0.88–0.95), 0.95 (0.91–0.99), 0.80 (0.77–0.83), and 0.73 (0.64–0.82), respectively. The subgroup analysis revealed that pioglitazone, not rosiglitazone, was associated with a significantly lower risk of hospitalization for all-cause pneumonia [0.85 (0.82–0.89)]. Longer cumulative duration and higher cumulative dose of pioglitazone were associated with further lower adjusted hazard ratios in these outcomes compared to no-use of TZDs. DISCUSSION: This cohort study demonstrated that TZD use was associated with significantly lower risks of hospitalization for pneumonia, invasive mechanical ventilation, and death due to pneumonia in patients with T2D. Higher cumulative duration and dose of pioglitazone were associated with a further lower risk of outcomes. |
format | Online Article Text |
id | pubmed-9981669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99816692023-03-04 Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes Yen, Fu-Shun Wei, James Cheng-Chung Hung, Yu-Tung Hsu, Chung Y. Hwu, Chii-Min Hsu, Chih-Cheng Front Microbiol Microbiology INTRODUCTION: We conducted this study to compare the risk of pneumonia between thiazolidinedione (TZD) use and nonuse in persons with type 2 diabetes (T2D). METHODS: We identified 46,763 propensity-score matched TZD users and nonusers from Taiwan’s National Health Insurance Research Database between January 1, 2000, and December 31, 2017. The Cox proportional hazards models were used for comparing the risk of morbidity and mortality associated with pneumonias. RESULTS: Compared with the nonuse of TZDs, the adjusted hazard ratios (95% CI) for TZD use in hospitalization for all-cause pneumonia, bacterial pneumonia, invasive mechanical ventilation, and death due to pneumonia were 0.92 (0.88–0.95), 0.95 (0.91–0.99), 0.80 (0.77–0.83), and 0.73 (0.64–0.82), respectively. The subgroup analysis revealed that pioglitazone, not rosiglitazone, was associated with a significantly lower risk of hospitalization for all-cause pneumonia [0.85 (0.82–0.89)]. Longer cumulative duration and higher cumulative dose of pioglitazone were associated with further lower adjusted hazard ratios in these outcomes compared to no-use of TZDs. DISCUSSION: This cohort study demonstrated that TZD use was associated with significantly lower risks of hospitalization for pneumonia, invasive mechanical ventilation, and death due to pneumonia in patients with T2D. Higher cumulative duration and dose of pioglitazone were associated with a further lower risk of outcomes. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9981669/ /pubmed/36876083 http://dx.doi.org/10.3389/fmicb.2023.1118000 Text en Copyright © 2023 Yen, Wei, Hung, Hsu, Hwu and Hsu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Yen, Fu-Shun Wei, James Cheng-Chung Hung, Yu-Tung Hsu, Chung Y. Hwu, Chii-Min Hsu, Chih-Cheng Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title_full | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title_fullStr | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title_full_unstemmed | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title_short | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
title_sort | thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981669/ https://www.ncbi.nlm.nih.gov/pubmed/36876083 http://dx.doi.org/10.3389/fmicb.2023.1118000 |
work_keys_str_mv | AT yenfushun thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes AT weijameschengchung thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes AT hungyutung thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes AT hsuchungy thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes AT hwuchiimin thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes AT hsuchihcheng thiazolidinedioneslowertheriskofpneumoniainpatientswithtype2diabetes |